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BRAF or c-KIT. The sr features, including targetable mutations in several kinases such as
uccessful development of therapies targeting these mutations hasMelanoma today is considered as a spectrum of melanocytic malignancies characterised by
resulted in new specific treatment options. These include vemurafenib, dabrafenib, tramet-
inib, imatinib and other kinase inhibitors that are selected when the respective mutation is
present.
The BRAF inhibitor vemurafenib has resulted in improved survival in patients with BRAF-
mutated advanced melanoma. Dabrafenib has shown similar efficacy. The MEK inhibitor
trametinib also improved overall survival. In addition, the MEK inhibitor MEK 162 was
investigated in a phase II clinical trial and showed promising efficacy in terms of response
rate and progression-free survival (PFS) in NRAS-mutated melanomas. After this first suc-
cess in the treatment of advanced melanoma, there is expectation that combinations of
kinase inhibitors will additionally improve overall survival rates and PFS in advanced
melanoma.
Copyright  2013 ECCO - the European CanCer Organisation. All rights reserved.ever, NRAS seems also to be involved in melanomas deriving
1. Introduction
Melanoma is the most common lethal cutaneous malignancy.
It arises from melanocytes that have their origin in the neural
crest. The genetic events and their relationship to the complex
interaction with the microenvironment transforming normal
melanocytes intomelanoma are under intensive investigation.
2. Molecular dissection of melanoma
In the last decade melanoma was dissected into several
molecular subgroups on the basis of genomic alterations,
including mutations, deletions and amplifications, in addition
to clinical features. These subgroups include BRAF, NRAS and
KIT mutated melanomas.
First, up to 50% of melanomas derived from the skin with-
out chronic sun damage (intermittently exposed to ultraviolet
(UV)) contain mutations in the gene encoding the serine–thre-
onine protein kinase BRAF. BRAF together with ARAF and
CRAF activates a second protein known as mitogen-activated
protein kinase kinase (MEK), which in turn activates extracel-
lular signal-regulated kinase (ERK).
Second, 20% of melanomas present with RAS mutations.
Most of the NRAS mutated melanomas are superficial,spreading melanomas (intermittently exposed to UV). How-
from giant congenital nevi. A recently published model for
congenital nevi [1] used a melanoma mouse model over-
expressing NRAS under the control of a tyrosinase promoter
in combination with loss of INK4a. The phenotype of these
mice closely resembles giant congenital nevi. In this model,
haplo-insufficiency of the transcription factor SOX10 pre-
vented melanoma formation.
Finally, minor percentages have activating mutations in
the KIT gene, most common in mucosal melanomas derived
from the genital regions [2,3] or mutations in GNA11 or GNAQ
genes in uveal melanomas [4,5]. Some of the targetable muta-
tions in the KIT gene are also found in acral and other muco-
sal (for example, penile or anal) melanomas but with lower
frequency. The KIT receptor protein tyrosine kinase is a trans-
membrane protein consisting of extracellular and intracellu-
lar domains. Most KIT mutations are located in exon 11,
which codes for the juxtamembrane domain, and in exon
13, which codes for a kinase domain.
Recently, deep exome sequencing shed further light on the
genomic landscape of melanoma [6,7]. Both publications
impressively demonstrated that UV light is responsible for
most mutations inmelanomas derived fromUV-exposed skin.rland. Tel.:
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ing mutations are UVB-dependent. Similar observations were
also reported by Krauthammer et al. In addition, both papers
provide evidence that RAC1 might be another driver mutation
for melanoma in addition to BRAF and NRAS. RAC1 is a mem-
ber of the Rho family of GPTases and therefore shares some
features with the RAS oncogenes. Interestingly these investi-
gations also identified deactivating mutations in phospha-
tases. These molecules might contribute as a feedback
mechanism during the activation of signalling pathways, and
defects in their function may contribute to tumour initiation
and progression. Obviously there aremany genetic alterations
inmelanoma. Itwill be crucial to identify drivermutations that
are promising targets for therapy in this huge landscape of ge-
netic alterations. These genetic alterations are definitely not
restricted to exomes. There are also relevant mutations in
non-coding DNA sequences such as promoter regions. Huang
et al. described two independent mutations in the promoter
of telomerase reverse transcriptase (TERT) [8]. Keeping these
data inmind, we can expectmanymore surprising discoveries
using these powerful techniques in the near future.
3. Breakthrough with kinase inhibitor therapy
in melanoma subgroups
The best-validated targeted drugs in melanoma are the selec-
tive BRAF inhibitors vemurafenib (PLX4032, ZelborafTM) and
dabrafenib (GSK2118436, TafinlarTM) as well as the LGX818
(Novartis) compound [9] that appears to have the highest
affinity for the catalytic domain of the kinase. All of them
are relatively selective for their intended target V600E BRAF,
with little cross-reactivity for wild-type BRAF and CRAF
[10,11]. A few other kinases are inhibited with 10- to 100-fold
of the concentration needed to inhibit V600 BRAF. These mol-
ecules selectively inhibit the growth of cells that harbour a
V600 BRAF mutation. In phase I clinical trials, where patients
were selectively enrolled on the basis of the presence of a tu-
mour BRAFV600E or BRAFV600K mutation, vemurafenib and dab-
rafenib both demonstrated evidence of tumour regression
early in the course of therapy in the majority of patients
[11–13]. Subsequent phase II and III trials designed to evaluate
overall disease control and survival in comparison with stan-
dard chemotherapy have documented the durability of re-
sponse in larger cohorts. In a phase II trial, vemurafenib
produced objective responses in 53% of 132 patients with
metastatic melanoma harbouring a BRAFV600E or BRAFV600K
mutation [14,15]. The median duration of response was
6.7 months. In a phase III trial with single-agent dacarbazine
as the control arm, overall survival (OS) was significantly im-
proved amongst 337 patients with BRAFV600E mutant meta-
static melanoma receiving vemurafenib compared with 338
patients who received dacarbazine (hazard ratio (HR) 0Æ37;
95% confidence interval (CI): 0.26–0.55; P < 0.001) [16]. Progres-
sion-free survival (PFS) was also significantly improved (haz-
ard ratio 0.26; 95% CI: 0.20–0.33; P < 0Æ001) and the response
rate was superior in the vemurafenib arm (48% objective re-
sponse rate versus 5%; P < 0Æ001). The benefit of vemurafenib
was maintained in an updated overall survival (OS) analysis
with approximately 10 months median follow-up, as demon-strated by the median OS with vemurafenib of 13.2 months
compared with 9.6 months with dacarbazine and a hazard ra-
tio (HR) for death of 0.62 (95% CI 0.49–0.77) in favour of vemu-
rafenib [17]. These data led to approval of vemurafenib in the
United States (US), European community and Switzerland.
Dabrafenib was compared with dacarbazine (random ratio
3:1) in a phase III trial in patients with previously untreated
stage IV or unresectable stage III melanoma harbouring the
BRAFV600 mutation. Median PFS was 5.1 months for dabrafe-
nib (187 patients) and 2.7 months for dacarbazine (63 pa-
tients), with an HR of 0.30 (95% CI: 0.18–0.51; P < 0.0001) [18].
This drug was recently approved by the Food and Drug
Administration (FDA) in the US.
In summary, vemurafenib and dabrafenib have both dem-
onstrated impressive clinical efficacy with response rates in
the region of 50% in V600 BRAF mutated advanced melanoma
[11,12,19]. Although the response duration is highly variable,
as shown by these phase II and phase III trials, these results
are a breakthrough in melanoma treatment.
Furthermore, multiple in vitro studies have demonstrated
that mutated BRAF signalling is mediated via MEK and ERK
[20]. Thus, selective MEK inhibitors have also shown efficacy
in patients with BRAF mutant metastatic melanoma. Selu-
metinib was the first allosteric, selective MEK inhibitor to be
evaluated in a phase II clinical trial in patients with meta-
static melanoma [21]. This agent produced an objective re-
sponse rate in patients with BRAF mutant tumours, whereas
no response was observed in wild-type tumours, reinforcing
the importance of selecting a specific patient population.
The addition of selumetinib to dacarbazine has resulted in
prolonged PFS in BRAF mutated metastatic melanoma [22]
and was the first agent to show clinical activity in uveal mel-
anoma when compared to temozolomide [23]. Trametinib is
another, orally available selective inhibitor of MEK1 and
MEK2. It demonstrated a reasonable objective response rate
and an improved survival compared to chemotherapy in BRAF
mutant melanoma. The median PFS was close to 5 months
using the MEK inhibitor in comparison to 1.5 months in the
chemotherapy group. After 6 months, there was an improve-
ment in the overall survival rate in the trametinib group of
81% (versus 67% in the chemotherapy group). Trametinib
(MekinistTM) was recently approved by the FDA for the treat-
ment of patients with unresectable or metastatic melanoma
with BRAF V600E or V600K mutation.
The combination of these kinase inhibitors clearly shows
further encouraging data. The combination treatment with
dabrafenib and trametinib was analysed with different
dosages in 247 BRAF V600 mutated melanoma patients. Med-
ian PFS was significantly improved at 9.4 months for the pa-
tients treated with 150 mg dabrafenib twice daily and 2 mg
trametinib daily, as compared with 5.8 months for the pa-
tients treated with dabrafenib alone (HR for progression or
death, 0.39; 95%CI, 0.25–0.62; P < 0.001). The rate of complete
or partial response in the combination group was 76% (com-
pared with 54% with monotherapy (P = 0.03) [24]. In other
words, the combination of BRAF and MEK inhibitors results
in an increased response rate and prolonged PFS [24]. Today,
there are several phase III clinical trials that compare the re-
sponse rates and the PFS in BRAF mutated patients for mono-
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Lito et al. have investigated the ERK-dependent feedback
mechanism during BRAF inhibition using a selective inhibitor.
They could clearly show that a BRAF inhibitor blocks RAF
monomers, resulting in RAF dimer formation. These dimer
feedback mechanisms are decreased. The addition of a MEK
inhibitor can overcome this problem and enhance the inhibi-
tion of the pathway and antitumour efficacy [25].
In vitro investigations using NRAS mutant melanoma cell
lines have suggested that MEK inhibitors may be useful in this
genetic background. A recent clinical trial using the MEK1/2
inhibitor MEK 162 in a phase II clinical trial has confirmed
that advanced NRAS mutant metastatic melanoma can be
successfully treated in patients. A response rate of approxi-
mately 25% was found, with a PFS similar to that observed
using MEK inhibitors in BRAF mutant metastatic disease
[26]. Other MEK inhibitors have been investigated in NRAS
mutated melanomas with some promising results.
Until recently, most clinical trials investigating immuno-
modulation, chemotherapy or targeted therapy have excluded
patients with brain metastasis due to concerns about drug
penetration through the blood–brain barrier and symptoms
such as intracranial bleeding resulting in life-threatening
consequences. Lately, the urgent need for medical treatment
of this patient population led to a trend change. There are re-
cent data [27] using the anti-CTLA-4 antibody ipilimumab at a
dose of 10 mg/kg every 3 weeks for four cycles in melanoma
patients with brain metastasis, with a response rate of 16%
in asymptomatic and 5% in symptomatic patients. A recently
reported trial [13] on dabrafenib in asymptomatic patients
with BRAF-mutated melanoma and at least one measurable
brain metastasis between 5 mm and 40 mm in diameter has
further demonstrated clinical activity. Moreover, in a pilot
study [28] of 24 symptomatic, very advanced melanoma pa-
tients with brain metastasis and harbouring a BRAF V600
mutation were treated safely and effectively with vemurafe-
nib, improving patients’ performance status and quality of
life. Further clinical trials – including combined therapies
with other inhibitors, with immunotherapy and with stereo-
tactic radiosurgery – are needed in the near future.
Both BRAF and MEK inhibitors have a very peculiar side-ef-
fect profile. As recently reported, BRAF inhibitors are charac-
terised by activating germline mutations of RAS and lead to
cutaneous side effects recently defined as RASopathic [29].
They involve both epidermis and adnexa and include inflam-
matory disorders such as maculopapular exanthema, follicu-
lar rash or pruritus, hair and nail changes, as well as
keratinocytic proliferations such as keratosis pilaris, palmopl-
antar hyperkeratosis, acanthopapilloma, keratoacanthoma
and squamous-cell carcinoma [30]. Melanocytic disorders
and proliferations have also been observed. In particular,
vemurafenib causes an important UVA-dependent phototox-
icity [31] that needs adequate UV protection. Dabrafenib, on
the other hand, does not seem to cause phototoxicity reac-
tions [30]. Its most common adverse events include skin-re-
lated toxic effects, fever, fatigue, arthralgia, and headache [18].
MEK inhibitors can cause papulopustular rashes, xerosis
cutis (often associated with fissured finger tips), diarrhoea,
nausea, vomiting, fatigue and blurred vision [32]. Moreover,self-limiting retinopathy-like dose-dependent retinal disor-
ders with early onset have been described [33]. Only one of
the seven described patients was symptomatic. The retinal
disorders were transient and resolved even during continua-
tion of MEK therapy. However, a close monitoring of the retina
with a specific mark on sub-retinal exudates is highly recom-
mended. The cutaneous side effects during MEK inhibition
are similar to those observed with epithelial growth factor
receptor (EGFR) inhibitors [34]. Notably, in a recently con-
ducted trial, cutaneous adverse events were observed in over
85% of the patients [35]. This emphasises the importance of
regular dermatological follow-up examinations. Thus, regular
skin examination andmanagement by experienced dermatol-
ogists, as well as continuous prophylactic photo-protection,
including a UVA optimised sun screen, are mandatory.
The combination of BRAF and MEK inhibitors interestingly
seems to reduce the common cutaneous side effects [24].
The impressive progress observed with the use of kinase
inhibitors is unfortunately limited by the development of
resistance that is observed after 6 months on average using
BRAF inhibitor monotherapy and after 9–10 months using
BRAF–MEK inhibitor combination therapy. There is intensive
research ongoing to understand the mechanisms behind this
clinically very relevant phenomenon. Most investigations
have been performed in vitro [36]. It remains unclear which
resistance mechanisms are the most frequent in vivo in hu-
mans. A recent study using human melanoma xenografts in
a nude mouse model has shown that melanoma cells can
transcriptionally up-regulate the BRAF molecule in order to
compensate the inhibition by vemurafenib. If vemurafenib
is removed from the system, there is an over-stimulation of
the pathway resulting in decreased proliferation, probably re-
lated to oncogene-driven senescence. As a consequence,
resistance can be delayed by pulsed therapy with vemurafe-
nib rather than continuous dosing [37]. This observation is
interesting and needs to be further investigated in the clinical
setting in the near future.
In contrast to BRAF mutated melanoma, the kinase
inhibitor imatinib has proven efficacy in patients with ad-
vanced melanoma harbouring KIT mutations [38]. KIT muta-
tions are found at low frequencies (610%) in melanomas
arising from mucosal or acral lentiginous surfaces [39]. As
the vast majority of patients with metastatic melanoma suf-
fer from primary tumours on glabrous skin (trunk, extremi-
ties, and head/neck), the number of patients in the
metastatic setting with mutated KIT is small. Durable re-
sponses were observed in 16% of a 51-patient cohort with
either mutations or amplifications in KIT [40]. In a phase II
trial, in which 43 patients with KIT mutations or amplifica-
tion were enrolled, 23% of patients had objective responses
[41]. In both studies, certain mutations in exon 11 and 13
of c-KIT (particularly L576P mutation in exon 11) were asso-
ciated with the highest response rate. In addition Nilotinib,
a tyrosine kinase inhibitor used in imatinib-resistant
chronic myelogenous leukaemia (CML), seems another
promising agent in the treatment of KIT mutated metastatic
melanoma and is currently under clinical investigation.
Thus, sensitivity to KIT inhibition exists in metastatic mela-
noma [21] but it is confined to a subset of this already small
subpopulation of patients.
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biology of melanomas has resulted in powerful targeted thera-
pieswith impact on progression-free and overall survival. Ongo-
ing research is focusedon resistancemechanismsandstrategies
to overcome them [36]. In order to further improve the outcome
in this still poor-prognosis population, patients should be
encouraged to participate in well-designed clinical trials.Conflict of interest statement
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